Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X:

“Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: Secondary analysis of a controlled randomized clinical trial.

a differential long-term benefit from tamoxifen therapy was observed between premenopausal and postmenopausal estrogen receptor–positive and HER2-negative BC patients. Clinical low-risk postmenopausal patients had a long-term benefit.
for premenopausal patients, the benefit was seen for few of the good prognosis tumor characteristics, and importantly, and not previously shown, the benefit was only seen to last beyond 10 years for genomic low-risk tumors.
there is a need for improved long-term treatment predictive markers, especially for premenopausal breast cancer patients, together with improved treatment strategies to address the challenges of late disease recurrence.”

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

Authors: Annelie Johansson, MSc, PhD, Huma Dar, MSc, PhD, Anna Nordenskjöld, MD, PhD, Gizeh Perez-Tenorio, MSc, PhD, Nicholas P Tobin, MSc, PhD, Christina Yau, PhD, Christopher C Benz, MD, Laura J Esserman, MD, Laura J van ‘t Veer, MSc, PhD, Bo Nordenskjöld, MD, PhD, Olle Stål, MSc, PhD, Tommy Fornander, MD, PhD, Linda S Lindström, MSc, PhD

Long-term tamoxifen benefit varies by menopausal status